Monthly Archives: January 2012

Enforcing anti-kickback laws: a powerful deterrent against ghost-writing in medicine

Posted on January 26, 2012 by

Share The Obama administration recently made it clear that it will require drug companies to disclose the payments they make to doctors for research, consulting, speaking, travel and entertainment under the new health care law — see the New York … Continue reading →

Posted in antidepressants, conflicts of interest, continuing medical education, drug marketing, ghostwriting, pharmaceutical industry, university industry collaboration | Tagged , , , , , | Leave a comment

From the Pentagon Papers to Allen Jones: Why it’s so hard to be a whistleblower

Posted on January 18, 2012 by

Share Allen Jones, the whistleblower in an ongoing landmark trial against the pharmaceutical giant Johnson & Johnson, was very much on my mind this past weekend. I was participating in a workshop to develop curriculum to teach college students about … Continue reading →

Posted in antipsychotic drugs, conflicts of interest, drug marketing, expert testimony, media coverage, pharmaceutical industry, whistleblowing | Tagged , , , , , , , | 5 Comments

Here’s to a New Year without our own breast implant scandal

Posted on January 5, 2012 by

Share In preparing for the holidays, you may have missed the French scandal over the defective artificial breasts implanted in hundreds of thousands of women. According to NPR, an estimated 400,000 women worldwide have received the faulty implants, and 30,000 … Continue reading →

Posted in Uncategorized | 1 Comment